

#	Cancer Type	Goal of Therapy	Regimen	Incremental Drug Cost	Outcomes
8520	DLBCL – non-GCB	primary	lenalidomide +R-CHOP	\$26,540	OS↑30%
508	Breast – HER-2 +	adjuvant	trastuzumab +chemo	\$76,601	↑ ^{8yr} 9% HR- ↑ ^{8yr} 4% HR+ ? HR+LN0/1
502	Breast – HER-2 +	palliative	trebananib +paclitaxel +trastuzumab	\$170,000**	?PFS/RR
5027	Prostate – castrate resistant	palliative	cabozantinib +abiraterone	\$32,521	? PSA↓
507	Breast – HER-2 +	neoadjuvant	bevacizumab +trastuzumab +docetaxel	\$77,267	=
500	Breast – HER-2 –	adjuvant	bevacizumab +chemo	\$129,460	=

Clinically meaningful improvement in patient outcomes



Lower value

Higher cost with no improvement in outcomes

* ASP+6% for infused drugs and AWP for oral drugs

** Not yet marketed. Estimated at \$10,000/month based on costs of similar new agents.